Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada
NCT ID: NCT04184336
Last Updated: 2022-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2016-01-31
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Meningococcal C Vaccine Programmes in Canadian Children
NCT00936962
Canadian Rotavirus Surveillance Through the Immunization Monitoring Program Active (IMPACT)
NCT01633190
National Bacterial Meningitis Study
NCT04664569
Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults
NCT02583412
Immunogenicity After Two Doses of Meningococcal Outer Membrane Vesicle Vaccine MenBVac
NCT00450554
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. description of affected children and adults and the nature and outcome of the infection episodes
2. incidence rate determination in defined populations, by age, serogroup and study year
3. detailed study of the organisms recovered from cases
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Persons of all ages
Persons of all ages admitted between January 1, 2016 and December 31, 2022 with a positive result of Neisseria meningitidis isolated or detected by PCR from a normal sterile site, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy
surveillance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
surveillance
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
2. meningococci isolated only from respiratory tract, including conjunctiva, sinuses, middle ear/mastoid, throat, peritonsillar abscess, cervical lymph node, tracheal aspirate, bronchial lavage etc -
1 Minute
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
GlaxoSmithKline
INDUSTRY
Canadian Paediatric Society
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alberta Children's Hospital
Calgary, Alberta, Canada
Stollery Children's Hospital
Edmonton, Alberta, Canada
BC Children's Hospital
Vancouver, British Colombia, Canada
Children's Hospital Research Institute of Manitoba
Winnipeg, Manitoba, Canada
Eastern Health Janeway Children's and Rehabilitation Centre
St. John's, Newfoundland and Labrador, Canada
IWK Health Centre
Halifax, Nova Scotia, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
CHU- Sainte Justine
Montreal, Quebec, Canada
Montreal Children's Hospital
Montreal, Quebec, Canada
Centre Mere-Enfant Soleil CHU de Quebec
Québec, Quebec, Canada
Royal University Hospital
Saskatoon, Saskatchewan, Canada
McMaster's Children Hospital
Hamilton, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Taj Jadavji, MD
Role: primary
Wendy Vaudry, MD
Role: primary
Manish Sadarangani
Role: primary
Joanne Embree, MD
Role: primary
Natalie Bridger, MD
Role: primary
Karina Top, MD
Role: primary
Nicole Le Saux, MD
Role: primary
Shaun Morris, MD
Role: primary
Marc Lebel, MD
Role: primary
Jesse Papenburg, MD
Role: primary
Roseline Thibeault, MD
Role: primary
Ben Tan
Role: primary
Jeffrey Pernica, MD
Role: primary
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol: Study protocol
Document Type: Study Protocol: ID_NCT04184336
Related Links
Access external resources that provide additional context or updates about the study.
Description IMPACT public website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MENING
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.